MLV response to stroke without or with AAV-VEGF-C prophylaxis. (A–D) Characterization of tMCAO mice. (A) Images of LYVE-1+ MLVs at the COS in sham mice and mice at 1 d-, 3 d-, and 7 d-pso. (B and C) Quantification of the surface (B) and diameter (C) of MLVs at the different time points after stroke compared to the sham group (n = 4–8 mice/group, **P < 0.005, *P < 0.05 Mann-Whitney test). (D) Quantification by qPCR of Vegfc expression on the right hemisphere (forebrain) (n = 3–5 mice/group, *P < 0.05 Mann–Whitney test). (E–G) AAV-VEGF-C– or AAV-CTRL–treated tMCAO mice. (E) Confocal imaging of MLVs labeled with the indicated antibody in the COS. (F and G) Quantification of LYVE-1+ area (G) and diameter (H) at 7 d-pso (n = 6–8 mice/group, *P < 0.05, **P < 0.005; Mann–Whitney). Scale bar: 170 μm (A and E).
Figure 4.

MLV response to stroke without or with AAV-VEGF-C prophylaxis. (A–D) Characterization of tMCAO mice. (A) Images of LYVE-1+ MLVs at the COS in sham mice and mice at 1 d-, 3 d-, and 7 d-pso. (B and C) Quantification of the surface (B) and diameter (C) of MLVs at the different time points after stroke compared to the sham group (n = 4–8 mice/group, **P < 0.005, *P < 0.05 Mann-Whitney test). (D) Quantification by qPCR of Vegfc expression on the right hemisphere (forebrain) (n = 3–5 mice/group, *P < 0.05 Mann–Whitney test). (E–G) AAV-VEGF-C– or AAV-CTRL–treated tMCAO mice. (E) Confocal imaging of MLVs labeled with the indicated antibody in the COS. (F and G) Quantification of LYVE-1+ area (G) and diameter (H) at 7 d-pso (n = 6–8 mice/group, *P < 0.05, **P < 0.005; Mann–Whitney). Scale bar: 170 μm (A and E).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal